Compare Moderna, Inc. (MRNA) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs TKO Group Holdings Inc — how do they compare? Moderna, Inc. trades at $63.75 (market cap $24.18B), while TKO Group Holdings Inc trades at $195.14 (market cap $14.24B). The key difference: Moderna, Inc. is the larger of the two by market cap, and TKO Group Holdings Inc pays a 1.6% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TKO | |
|---|---|---|
Market Cap | $24.18B | $14.24B |
Sector | Health | Technology |
52-Week High | $81.80 | $224.96 |
52-Week Low | $22.36 | $176.49 |
Enterprise Value | $20.33B | $18.60B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
TKO trades at $195.14, up 3.02% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. Recent Q2 2026 results showed revenue of $1.55 billion, an 18% YoY increase, though EPS of $1.34 missed expectations. The company raised full-year guidance, reflecting confidence in media rights and live events. Analyst consensus is strongly bullish with an average price target of $228.17, representing 17% upside from current levels.
TKO's growth trajectory is supported by expanding media deals and global events, but high valuation multiples (P/E 68.33) pose risks if execution falters. Key opportunities include continued revenue momentum from UFC and WWE, while risks involve earnings volatility and competitive pressures. The stock remains attractive for growth-oriented investors despite premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
